Bruker Appoints Bonnie H. Anderson to its Board of Directors
September 08 2020 - 7:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that it has
appointed Bonnie H. Anderson to serve on its board of directors,
effective as of September 3, 2020.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200908005326/en/
(Photo: Business Wire)
Ms. Anderson is Co-Founder, Chairman of the Board and CEO of
Veracyte, a global genomic diagnostics company that improves
patient care by informing diagnosis and treatment decisions in
cancer and other diseases. Before Veracyte, Ms. Anderson spent 18
years at Beckman Coulter, where she held leadership positions
across the global life sciences and diagnostic business segments,
including flow cytometry. After she retired from Beckman Coulter,
Ms. Anderson was brought into a life sciences incubator formed by
Kleiner Perkins, Versant Ventures and TPG Biotech, where she
developed the concept for Veracyte. Veracyte is now a public global
company with a market capitalization of nearly $2 billion.
"We are very pleased to welcome Bonnie to the Bruker board, and
we especially value her entrepreneurial success, and her many years
of genomics testing and diagnostics business expertise. She also
has deep insights into oncology, hematology and immunology
diagnostic tools and clinical workflows," said Frank Laukien,
Bruker’s Chairman, President and CEO. "The addition of Bonnie to
our board is very timely as we continue to evolve our Project
Accelerate initiatives in multiomics life-science and clinical
research tools towards molecular diagnostics solutions. Bonnie
shares our goals to serve life science research and medicine with
leading measurement tools and diagnostic solutions, and to enhance
value for all of Bruker’s stakeholders."
“I am honored to be appointed to the Bruker board, and I am
looking forward to contributing to the success of such a dynamic
and innovative company. I have admired the breakthrough work Bruker
does in advancing life science and clinical research for many
years, and I am thrilled to join such an impressive board,” said
Ms. Anderson.
“Our board regularly evaluates its composition to ensure it
includes the appropriate skills, experience and perspectives to
support Bruker’s strategic direction. With Bonnie’s addition, seven
new Bruker directors will have joined Bruker’s board in the past
five years, including three women,” said Marc Kastner, the Chair of
Bruker’s Nominating & Governance Committee.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science research, in applied and pharma applications, in microscopy
and nanoanalysis, and in industrial applications, as well as in
cell biology, preclinical imaging, clinical phenomics and
proteomics research, clinical microbiology and infectious disease
molecular diagnostics. For more information, please visit:
www.bruker.com.
Forward Looking Statements
Any statements contained in this press release which do not
describe historical facts may constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding management’s expectations
for future financial and operational performance, business
strategy, business outlook and Board performance. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those indicated,
including, but not limited to, risks and uncertainties relating to
continued adverse changes in conditions in the global economy and
volatility in the capital markets, the impact of the COVID-19
coronavirus outbreak and our ability to recover from its effects,
the integration and assumption of liabilities of businesses we have
acquired or may acquire in the future, fluctuations in foreign
currency exchange rates, our material weaknesses in internal
controls, our ability to successfully implement our restructuring
initiatives, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, loss of key personnel, dependence on
collaborative partners, key suppliers and contract manufacturers,
capital spending and government funding policies, changes in
governmental regulations, the use and protection of intellectual
property rights, litigation, and other risk factors discussed from
time to time in our filings with the Securities and Exchange
Commission, or SEC. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2019 and our subsequently filed Form 10-Qs. We
expressly disclaim any intent or obligation to update these
forward-looking statements other than as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005326/en/
Miroslava Minkova Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024